Toronto Dominion Bank Cuts Stake in Elanco Animal Health (NYSE:ELAN)

Toronto Dominion Bank lowered its holdings in shares of Elanco Animal Health (NYSE:ELAN) by 13.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,813 shares of the company’s stock after selling 6,561 shares during the quarter. Toronto Dominion Bank’s holdings in Elanco Animal Health were worth $1,447,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Geode Capital Management LLC purchased a new position in Elanco Animal Health during the 4th quarter valued at approximately $18,592,000. Deutsche Bank AG purchased a new position in Elanco Animal Health during the 4th quarter valued at approximately $60,000. Comerica Bank purchased a new position in Elanco Animal Health during the 1st quarter valued at approximately $384,000. First Allied Advisory Services Inc. purchased a new position in Elanco Animal Health during the 1st quarter valued at approximately $228,000. Finally, First Mercantile Trust Co. purchased a new position in Elanco Animal Health during the 1st quarter valued at approximately $65,000.

In other Elanco Animal Health news, insider Todd S. Young purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $26.57 per share, with a total value of $265,700.00. Following the purchase, the insider now owns 28,883 shares of the company’s stock, valued at $767,421.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Deborah Turner Kochevar purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average cost of $27.95 per share, with a total value of $27,950.00. Insiders have purchased a total of 112,780 shares of company stock valued at $3,003,162 over the last three months. 0.04% of the stock is owned by corporate insiders.



Shares of NYSE:ELAN traded down $0.61 during trading on Wednesday, hitting $27.47. The company had a trading volume of 34,977 shares, compared to its average volume of 5,097,370. The stock has a market cap of $10.49 billion and a price-to-earnings ratio of 23.28. Elanco Animal Health has a one year low of $25.51 and a one year high of $37.61. The company has a fifty day simple moving average of $28.89 and a two-hundred day simple moving average of $31.54. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.07 and a quick ratio of 1.71.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.02. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. The business had revenue of $781.60 million during the quarter, compared to analyst estimates of $781.49 million. The firm’s revenue was up 1.5% compared to the same quarter last year. On average, equities research analysts anticipate that Elanco Animal Health will post 1.08 earnings per share for the current year.

Several equities analysts have weighed in on ELAN shares. UBS Group upgraded Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their price target for the company from $31.00 to $30.00 in a report on Thursday, August 15th. Zacks Investment Research lowered Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Friday, September 6th. Goldman Sachs Group assumed coverage on Elanco Animal Health in a research note on Monday, September 9th. They issued a “positive” rating for the company. They noted that the move was a valuation call. Bank of America lowered Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price objective for the company. in a research note on Monday, August 26th. Finally, Guggenheim assumed coverage on Elanco Animal Health in a research note on Wednesday, May 22nd. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company’s stock. Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $33.64.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.